-Reuters
Barclays Maintains Equal-Weight on Biogen, Raises Price Target to $275
Barclays analyst Carter Gould maintains Biogen (NASDAQ:BIIB) with a Equal-Weight and raises the price target from $200 to $275.
Related Posts
Cathie Wood Says ‘Fed Seems To Be Playing With Fire’; Aggressive Interest Rate Hikes Could Be A ‘Mistake’
The Federal Reserve began to hike the fed funds rate last month, after maintaining it at very accommodative levels since the outbreak of the pandemic in early 2020.
Colony Bancorp Says Board Of Directors Authorized $12M Stock Buyback Program Through The End Of 2023
The Board of Directors authorized a $12 million stock buyback program that will be in place through the end of 2023. This equates to approximately 5% of the current shares outstanding at recent
Poll Or No Poll, Elon Musk Likely Intends To Sell Tesla Stock In Face of $15B Tax Bill: Report
Tesla Inc (NASDAQ: TSLA) CEO Elon Musk faces a whopping $15 billion tax bill and that may have reportedly prompted him to consider selling some of his holdings in the electric vehicle company.